- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06207006
E-intervention on Subclinical Fear of Cancer Recurrence
January 12, 2024 updated by: The University of Hong Kong
Conquering Fear Online: a Pilot Randomised Controlled Trial Assessing the Efficacy and Feasibility of an Internet-based Self-management Intervention on Subclinical Fear of Cancer Recurrence
The present study aims to adapt a metacognition-based ConquerFear-HK to an internet-based self-management intervention, namely eConquerFear-HK and evaluate in a randomised controlled trial, its feasibility, utility, and potential effectiveness on fear of cancer recurrence reduction among local Chinese cancer survivors with subclinical fear of cancer recurrence.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
A pilot randomised controlled feasibility trial will used to test the feasibility, utility, and potential effectiveness of an internet-based self-management intervention for fear of cancer recurrence among local Chinese cancer survivors with subclinical fear of cancer recurrence.
The following hypotheses will be tested:
- There will be a greater FCR improvement in cancer survivors receiving eConquerFear-HK intervention vs those in the active control group.
- There will be a greater MCQ reduction in cancer survivors receiving eConquerFear-HK intervention vs those in the active control group.
- There will be greater improvements in secondary outcomes (psychological distress and quality of life) in cancer survivors receiving eConquerFear-HK intervention vs those in the active control group.
- Cancer survivors receiving eConquerFear-HK intervention will perceive the intervention useful for managing their FCR and be satisfied with the intervention.
- Cancer survivors receiving eConquerFear-HK intervention will show high completion rates.
Study Type
Interventional
Enrollment (Estimated)
48
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Danielle Ng, PhD
- Phone Number: 39179897
- Email: dwlng@hku.hk
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Cantonese- or Mandarin-speaking Chinese cancer survivors
- recently diagnosed with potentially curable (stage 0 to III) colorectal or breast cancer
- had recently completed surgery as primary treatment
- have completed hospital-based adjuvant treatments (including radiotherapy and chemotherapy) within the past six months
- scored 13 to 21 on the fear of cancer recurrence-short form will be recruited.
Exclusion Criteria:
- non-Chinese ethnicity
- metastatic cancer
- with current diagnosis of depression or psychosis or are currently receiving psychological treatments
- language or intellectual difficulties that prevent them from understanding the intervention content
- having limited or no Internet access.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: eConquerFear-HK
Participants in the eConquerFear-HK intervention group will receive six online modules with each containing educational text, illustrative graphics, interactive exercises, and brief videos.
Every module will teach a specific topic, such as self-examination and medical surveillance, values-based goal setting, attention training, detached mindfulness, worry management and treatment summary and relapse prevention.
|
The key goals of the intervention are to: (i) teach strategies for controlling worry and excessive threat monitoring; (ii) modify underlying unhelpful MCQ beliefs about worry; (iii) develop appropriate monitoring and screening behaviours, (iv) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (v) clarify values and encourage engagement in values-based goal setting.
|
Active Comparator: Basic Cancer Care
Participants in the control group will receive six videos, which were designed to provide comprehensive lifestyle guidance (e.g., relaxation techniques, diet and physical activity advices) to help with survivors' maintenance of health in long-term.
|
Basic Cancer Care serves as an active comparator and is not developed specifically to target fear of cancer recurrence through modifying participants' cognitive beliefs.
Participants in this arm will receive 6 videos about relaxation, generic dietary and exercise knowledge.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of subject recruitment
Time Frame: baseline
|
number of participants consent and being randomized/number of eligible patients x 100
|
baseline
|
Rate of subject retention
Time Frame: baseline,3-months post-intervention and 6-months post-intervention
|
number of participants who complete follow-up assessments at 3 and 6 months post-baseline/number of participants enrolled x 100
|
baseline,3-months post-intervention and 6-months post-intervention
|
Adherence rate to intervention
Time Frame: the immediate post-intervention
|
number of participants who complete the intervention/number of being allocated to attend the intervention x 100
|
the immediate post-intervention
|
Intervention utility
Time Frame: the immediate post-intervention
|
Intervention utility will be assessed using the site use metrics, including total number of log-ins
|
the immediate post-intervention
|
Acceptability of the intervention
Time Frame: the immediate post-intervention
|
Acceptability of the intervention will be assessed using the 22-item measure, which was adopted from the 31-item measure designed to assess the general views on the presentation and content of information in a decision aid intervention for treatment decision making.
It assess the comprehensibility of the intervention content and also its utility using 4- (1 = "Poor"; 2 = "Fair"; 3 = "Good"; 4 = "Excellent") or 5-option (1 ="strongly disagree"; 5 = "strongly agree") categorical responses, respectively.
Higher scores indicate better acceptability.
|
the immediate post-intervention
|
Change of fear of cancer recurrence
Time Frame: Baseline, the immediate post-intervention, 3-months post-intervention and 6-months post-intervention
|
Fear of cancer recurrence.
FCR will be assessed using the Chinese 42-item Fear of Cancer Recurrence Inventory (FCRI) at four assessment points (T0-T3).(5)
FCRI comprises seven subscales: trigger, severity, psychological distress, functional impairment, reassurance, insights and coping strategies measured using 5-point Likert scales (0 = "never"; 4 = " a great deal or all the time").(5)
Total scores range from 0 to 168; with higher scores indicating higher FCR.
|
Baseline, the immediate post-intervention, 3-months post-intervention and 6-months post-intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of quality of life
Time Frame: Baseline, the immediate post-intervention, 3-months post-intervention and 6-months post-intervention
|
Quality of life will be measured by the Chinese version of the 30-item European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30), consisting of five functional subscales (physical, role, emotional, cognitive, and social functioning), three symptom subscales (pain, fatigue and nausea/vomiting), a global health subscale, five single symptom items (e.g., sleep disturbance, dyspnea, appetite loss, constipation, and diarrhea), and an single item for financial difficulty.
The score range is 0-100.
High scores on the functional and global health subscales indicate better functioning and QoL, respectively.
High scores on the symptom subscale or item indicate more symptom(s).
|
Baseline, the immediate post-intervention, 3-months post-intervention and 6-months post-intervention
|
Change of general psychological distress
Time Frame: Baseline, the immediate post-intervention, 3-months post-intervention and 6-months post-intervention
|
e Chinese 14-item Hospital Anxiety and Depression Scale (HADS),(21) comprising two 7-item subscales that measure anxiety and depression.
Each subscale total scores range from 0 to 21 with higher scores suggesting higher distress.
|
Baseline, the immediate post-intervention, 3-months post-intervention and 6-months post-intervention
|
Attitude towards internet assessed using categorical Likert scales
Time Frame: the immediate post-intervention
|
Attitude towards internet will be assessed using a 6 points-categorical Likert scale (0-5) asking if they find internet easy to use.
Higher scores indicate more positive attitude towards internet.
|
the immediate post-intervention
|
Treatment satisfaction
Time Frame: the immediate post-intervention
|
A 17-item treatment satisfaction questionnaire, originally designed to evaluate overall satisfaction with the intervention in our current RCT of ConquerFear-HK, will be used.
The first 9 items will be assessed using a 5 points-categorical Likert scale (1-5) Higher scores indicate higher satisfaction.
The remaining questions are open-questions.
|
the immediate post-intervention
|
Change of metacognition
Time Frame: Baseline, the immediate post-intervention, 3-months post-intervention and 6-months post-intervention
|
Metacognition will be assessed at T0-T3 using the 30-item Metacognitions Questionnaire- 30 (MCQ-30), consisting of five subscales assessing Positive beliefs about worry, Negative beliefs about worry, Cognitive Self-Consciousness, Cognitive Confidence, and Need to control thoughts.
A 4 points-categorical Likert scale (1-4) will be used.
Higher scores indicate worse metacognition
|
Baseline, the immediate post-intervention, 3-months post-intervention and 6-months post-intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Danielle Ng, PhD, School of Public Health, The University of Hong Kong
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
March 1, 2024
Primary Completion (Estimated)
December 31, 2024
Study Completion (Estimated)
March 31, 2025
Study Registration Dates
First Submitted
December 12, 2023
First Submitted That Met QC Criteria
January 12, 2024
First Posted (Estimated)
January 15, 2024
Study Record Updates
Last Update Posted (Estimated)
January 15, 2024
Last Update Submitted That Met QC Criteria
January 12, 2024
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UW22-602
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
All IPD that underlie results in a publication will be available from the PI upon reasonable request.
IPD Sharing Time Frame
starting 6 months after publication
IPD Sharing Access Criteria
Information will be available from the PI upon reasonable request.
The author to review requests is the PI.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Palleon Pharmaceuticals, Inc.RecruitingMelanoma | Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | NSCLC | Non Small Cell Lung Cancer | Bladder Cancer | Colon Cancer | Urothelial Cancer | Oncology | CRC | Esophagogastric Junction Cancer | EGJUnited States
Clinical Trials on eConquerFear-HK
-
The University of Hong KongNot yet recruitingCancer | Fear of Cancer Recurrence
-
CuromeBiosciencesCompletedPrimary Sclerosing CholangitisKorea, Republic of
-
University College, LondonThe University of Hong KongUnknownDementia | Dementia, Vascular | Dementia, Mixed | Dementia With Lewy Bodies | Dementia of Alzheimer Type | Dementia Moderate | Dementia Severe | Dementia Frontal
-
Smith & Nephew, Inc.Active, not recruitingKnee Arthroplasty, TotalUnited States, Australia, Canada, Belgium, Spain
-
HenKan Pharmaceutical Co., Ltd.Completed
-
The University of Hong KongNot yet recruitingChild DevelopmentHong Kong
-
Everfront Biotech Co., Ltd.Active, not recruitingAmyotrophic Lateral SclerosisTaiwan
-
The University of Hong KongCompleted
-
The University of Hong KongSydney Children's Hospitals Network; SAHKRecruitingAutism Spectrum DisorderHong Kong
-
National Institute of Allergy and Infectious Diseases...Johns Hopkins Bloomberg School of Public HealthCompletedVirus Diseases | InfluenzaUnited States